Core Insights - Rippling, an HR software startup, raised $450 million in Series G funding, achieving a valuation of $16.8 billion, focusing on global revenue growth over immediate profitability [1][4][5] Funding and Valuation - The funding round included participation from notable investors such as Y Combinator, Elad Gil, Sands Capital, GIC, and Goldman Sachs Growth [2] - The new valuation of $16.8 billion marks an increase from the previous valuation of $13.5 billion in early 2024 [4] Employee Equity and IPO Plans - Rippling plans to repurchase up to $200 million of equity from current and former employees through a tender offer, which may become an annual event [2][3] - The CEO stated that the company does not have immediate plans for an IPO, emphasizing the need for profitability before considering going public [4][6] Business Performance and Strategy - Rippling has surpassed $100 million in annual recurring revenue and serves over 20,000 customers with a suite of more than 20 products [5] - The company is prioritizing growth over profitability, indicating a strategic choice to expand rapidly rather than slow down for immediate profit [6] Legal Challenges - Rippling is involved in ongoing legal disputes with competitor Deel, including allegations of corporate espionage, which have raised questions about competitive practices in the tech industry [7][8]

Cited by Barron's as one of the top financial websites to visit on the weekend, Financial Sense (www.financialsense.com) provides educational resources to the broad public audience through a daily podcast, editorials, current news and resource links on salient financial market issues. Begun in 1985 as a local talk radio program, Financial Sense Newshour (www.financialsense.com/financial-sense-newshour) is a weekly webcast with host Jim Puplava and top financial thinkers. Writing staff of Financial Sense inc ...

Once one of the hottest stocks around, Lululemon Athletica (LULU 1.72%) has largely been a lemon since peaking at more than $500 in December 2023. The company is still growing revenue, albeit at a modest pace, mostly driven by international expansion, while its gross margins have come under pressure from tariffs.Let's take a closer look at the company's most recent results to see whether a turnaround could be in the cards. A rudderless shipOne of the biggest problems with the Lululemon turnaround at this po ...

Docusign (DOCU 0.94%) went public in 2018 at a price of $29 per share, and by September 2021, the stock had soared more than tenfold to an all-time high of $310. The company's digital agreement management software experienced blistering demand during the COVID-19 pandemic, because it allowed businesses to continue closing deals even in the face of social restrictions and lockdowns.Unfortunately, demand tapered off when conditions returned to normal, and Docusign stock has since plummeted by 84% from its 202 ...

Company Overview - Omeros Corporation is an innovative, commercial-stage biotechnology company focused on discovering and developing first-in-class therapeutics for large-market and orphan indications, particularly in complement-mediated diseases, cancers, and addictive disorders [2] - The company's lead product, YARTEMLEA® (narsoplimab-wuug), is FDA-approved for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in patients aged two years and older [2] - Omeros is also advancing its pipeline, including OMS1029, a long-acting MASP-2 inhibitor that has completed Phase 1 clinical trials [2] Recent Developments - Omeros will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, focusing on advances in TA-TMA treatment [1] - The session will be co-chaired by notable experts and will feature presentations from leading professionals in the field [1] - Omeros has recently completed its first commercial shipments of YARTEMLEA to distributors, with orders from transplant centers beginning immediately [7] Strategic Partnerships - Novo Nordisk has acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other indications, along with associated intellectual property [3] - Omeros' pipeline also includes OMS527, a phosphodiesterase 7 inhibitor for cocaine use disorder, which is fully funded by the National Institute on Drug Abuse [3]

If you're nearing retirement, you may be getting increasingly excited about wrapping up your career and getting to enjoy a more flexible, relaxed schedule. But before you make your retirement official, it's important to ensure that you're prepared financially.Part of that means estimating your monthly spending to see what your bills might come to. It also means making sure you have enough income coming your way to cover your costs. But if you're expecting to get all of your retirement income from Social Sec ...

Core Viewpoint - The traditional 4% rule for retirees is considered too conservative in the current investment landscape, which offers modern income tools that can enhance investment strategies [1]. Group 1: Investment Strategy - A hybrid investment approach combining classic dividend growth stocks with Business Development Companies, REITs, and Closed End Funds can effectively boost investment income while achieving total returns comparable to traditional index funds [1]. - The strategy aims to create a balance between growth and income, allowing investors to capture total returns on par with the S&P 500 [1].

American Axle & Manufacturing (NYSE:DCH – Get Free Report) is one of 14 public companies in the “Motor Vehicle Parts & Accessories” industry, but how does it compare to its rivals? We will compare American Axle & Manufacturing to similar businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations. Get American Axle & Manufacturing alerts: ProfitabilityThis table compares American Axle & Manufacturing and its rivals’ net ma ...

American Axle & Manufacturing (NYSE:DCH – Get Free Report) is one of 14 public companies in the “Motor Vehicle Parts & Accessories” industry, but how does it weigh in compared to its rivals? We will compare American Axle & Manufacturing to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, earnings, risk and institutional ownership. Get American Axle & Manufacturing alerts: Valuation & EarningsThis table compares American Axle & Manufacturing and it ...

Get alerts: Venture Global, Caterpillar, and Deere & Company are the three Construction stocks to watch today, according to MarketBeat’s stock screener tool. Construction stocks are shares of companies whose primary business is building and related activities — including homebuilders, general contractors, infrastructure and commercial developers, and firms that supply construction materials and equipment. They are typically cyclical and sensitive to economic growth, interest rates, housing demand, and gov ...